Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHLOS
2022-502274-16-00Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Isotime inspiratory capacity. Started Sep 2023; status: completed.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-502274-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502274-16-00.